Simcere Pharmaceutical Group Limited in 1 story
The narratives 2096.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
2096.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Simcere is converting its China-based discovery and clinical capabilities into global value through oncology and immunology licensing partnerships.
Bear side
0 storiesNo bear-side stories for 2096.HK yet.